Bionpharma Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bionpharma (US): 4 reconciled FDA prescription therapies (90.4% 2025 to 2030 cliff risk), $9.9M 2024 CMS Part D & Medicaid spend, and $2,133 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure90.4%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$9.9M
2024 Medicare Part D Spend$6.6M
2024 Medicaid Spend$3.3M
California HCAI SB 17 FilingsSpecialty launch notice ($2,133 intro WAC)